The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Artificial intelligence (AI) is rapidly being integrated into every domain of healthcare, giving birth to a new class of tech ...

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

The deal also brings integration and execution risks. Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market ...

Management guides for $1.24 billion in 2025 revenues, a 79% YoY growth, bolstered by the Ambry Genetics acquisition and a rapidly growing TAM. Despite the deep selloff recently, I rank TEM a ...

Ambry Genetics drives innovation in diagnostics by launching cutting-edge genetic tests and technologies. Its broad collaborations, novel research projects, and networks for data sharing ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Researchers from Mass General Brigham , Harvard Medical School and Duke University School of Medicine have identified nearly ...

“Such a high rate of a false positives in this particular study was unexpected,” says study coauthor Stephany Tandy-Connor of Ambry Genetics, in a statement. She notes that differences in testing ...